Click here to get full coverage on Chipmakers Recap: Can VSTM stock double in next 5 years - July 2025 Short Interest & Smart Money Movement Tracker - moha.gov.vn

Chipmakers Recap: Can VSTM stock double in next 5 years - July 2025 Short Interest & Smart Money Movement Tracker  moha.gov.vn

Chipmakers Recap: Can VSTM stock double in next 5 years - July 2025 Short Interest & Smart Money Movement Tracker - moha.gov.vn

Click here to get full coverage on Insider Sell: Dan Paterson Sells 4,000 Shares of Verastem Inc (VSTM) - GuruFocus

Insider Sell: Dan Paterson Sells 4,000 Shares of Verastem Inc (VSTM)  GuruFocus

Insider Sell: Dan Paterson Sells 4,000 Shares of Verastem Inc (VSTM) - GuruFocus

Click here to get full coverage on Verastem (VSTM) Upgraded to Buy: Here's Why - Yahoo Finance

Verastem (VSTM) Upgraded to Buy: Here's Why  Yahoo Finance

Verastem (VSTM) Upgraded to Buy: Here's Why - Yahoo Finance

Click here to get full coverage on With Verastem Stock Surging, Have You Considered The Downside? - Trefis

With Verastem Stock Surging, Have You Considered The Downside?  Trefis

With Verastem Stock Surging, Have You Considered The Downside? - Trefis

Click here to get full coverage on Verastem (VSTM) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Zacks Investment Research

Verastem (VSTM) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?  Zacks Investment Research

Verastem (VSTM) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Zacks Investment Research

Click here to get full coverage on $VSTM stock is down 16% today. Here's what we see in our data. - Quiver Quantitative

$VSTM stock is down 16% today. Here's what we see in our data.  Quiver Quantitative

$VSTM stock is down 16% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Verastem (NASDAQ:VSTM) CEO Sells $21,000.00 in Stock - MarketBeat

Verastem (NASDAQ:VSTM) CEO Sells $21,000.00 in Stock  MarketBeat

Verastem (NASDAQ:VSTM) CEO Sells $21,000.00 in Stock - MarketBeat

Click here to get full coverage on Wall Street Analysts Think Verastem (VSTM) Could Surge 68.11%: Read This Before Placing a Bet - Nasdaq

Wall Street Analysts Think Verastem (VSTM) Could Surge 68.11%: Read This Before Placing a Bet  Nasdaq

Wall Street Analysts Think Verastem (VSTM) Could Surge 68.11%: Read This Before Placing a Bet - Nasdaq

Click here to get full coverage on CEO Paterson Sells 6,000 ($63K) Of Verastem Inc [VSTM] - TradingView

CEO Paterson Sells 6,000 ($63K) Of Verastem Inc [VSTM]  TradingView

CEO Paterson Sells 6,000 ($63K) Of Verastem Inc [VSTM] - TradingView

Click here to get full coverage on Verastem Oncology drops despite Q3 double beat (VSTM:NASDAQ) - Seeking Alpha

Verastem Oncology drops despite Q3 double beat (VSTM:NASDAQ)  Seeking Alpha

Verastem Oncology drops despite Q3 double beat (VSTM:NASDAQ) - Seeking Alpha

Click here to get full coverage on Forecast Cut: Is Direxion Daily Dow Jones Internet stock a buy before new product rollout - 2025 Big Picture & Weekly Market Pulse Updates - moha.gov.vn

Forecast Cut: Is Direxion Daily Dow Jones Internet stock a buy before new product rollout - 2025 Big Picture & Weekly Market Pulse Updates  moha.gov.vn

Forecast Cut: Is Direxion Daily Dow Jones Internet stock a buy before new product rollout - 2025 Big Picture & Weekly Market Pulse Updates - moha.gov.vn

Click here to get full coverage on Can Verastem's (VSTM) Early KRAS Results Redefine Its Position in Oncology Innovation? - Yahoo Finance

Can Verastem's (VSTM) Early KRAS Results Redefine Its Position in Oncology Innovation?  Yahoo Finance

Can Verastem's (VSTM) Early KRAS Results Redefine Its Position in Oncology Innovation? - Yahoo Finance

Click here to get full coverage on Insider Sell: Dan Paterson Sells 6,000 Shares of Verastem Inc (V - GuruFocus

Insider Sell: Dan Paterson Sells 6,000 Shares of Verastem Inc (V  GuruFocus

Insider Sell: Dan Paterson Sells 6,000 Shares of Verastem Inc (V - GuruFocus

Click here to get full coverage on VERASTEM Earnings Results: $VSTM Reports Quarterly Earnings - Quiver Quantitative

VERASTEM Earnings Results: $VSTM Reports Quarterly Earnings  Quiver Quantitative

VERASTEM Earnings Results: $VSTM Reports Quarterly Earnings - Quiver Quantitative

Click here to get full coverage on Earnings Preview: Verastem (VSTM) Q2 Earnings Expected to Decline - Yahoo Finance

Earnings Preview: Verastem (VSTM) Q2 Earnings Expected to Decline  Yahoo Finance

Earnings Preview: Verastem (VSTM) Q2 Earnings Expected to Decline - Yahoo Finance

Click here to get full coverage on New Analyst Forecast: $VSTM Given 'Overweight' Rating - Quiver Quantitative

New Analyst Forecast: $VSTM Given 'Overweight' Rating  Quiver Quantitative

New Analyst Forecast: $VSTM Given 'Overweight' Rating - Quiver Quantitative

Click here to get full coverage on Verastem Oncology (VSTM): Assessing Valuation Following Promising KRAS G12D Pancreatic Cancer Trial Update - Yahoo Finance

Verastem Oncology (VSTM): Assessing Valuation Following Promising KRAS G12D Pancreatic Cancer Trial Update  Yahoo Finance

Verastem Oncology (VSTM): Assessing Valuation Following Promising KRAS G12D Pancreatic Cancer Trial Update - Yahoo Finance

Click here to get full coverage on Verastem Inc (VSTM) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Rising ... - Yahoo Finance

Verastem Inc (VSTM) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Rising ...  Yahoo Finance

Verastem Inc (VSTM) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Rising ... - Yahoo Finance

Click here to get full coverage on Verastem, Inc.'s (NASDAQ:VSTM) institutional investors lost 13% over the past week but have profited from longer-term gains - simplywall.st

Verastem, Inc.'s (NASDAQ:VSTM) institutional investors lost 13% over the past week but have profited from longer-term gains  simplywall.st

Verastem, Inc.'s (NASDAQ:VSTM) institutional investors lost 13% over the past week but have profited from longer-term gains - simplywall.st

Click here to get full coverage on Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025 - Business Wire

Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025  Business Wire

Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025 - Business Wire

Click here to get full coverage on Verastem climbs on Q2 beat as new ovarian cancer drug boosts topline - Seeking Alpha

Verastem climbs on Q2 beat as new ovarian cancer drug boosts topline  Seeking Alpha

Verastem climbs on Q2 beat as new ovarian cancer drug boosts topline - Seeking Alpha

Click here to get full coverage on Verastem (VSTM) CEO Paterson sells shares worth $32,145 - Investing.com

Verastem (VSTM) CEO Paterson sells shares worth $32,145  Investing.com

Verastem (VSTM) CEO Paterson sells shares worth $32,145 - Investing.com

Click here to get full coverage on $VSTM stock is up 16% today. Here's what we see in our data. - Quiver Quantitative

$VSTM stock is up 16% today. Here's what we see in our data.  Quiver Quantitative

$VSTM stock is up 16% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on New Analyst Forecast: $VSTM Given 'Buy' Rating - Quiver Quantitative

New Analyst Forecast: $VSTM Given 'Buy' Rating  Quiver Quantitative

New Analyst Forecast: $VSTM Given 'Buy' Rating - Quiver Quantitative

Click here to get full coverage on Verastem Inc (VSTM) President and CEO Dan Paterson Sells 6,000 S - GuruFocus

Verastem Inc (VSTM) President and CEO Dan Paterson Sells 6,000 S  GuruFocus

Verastem Inc (VSTM) President and CEO Dan Paterson Sells 6,000 S - GuruFocus

Click here to get full coverage on VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval - Nasdaq

VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval  Nasdaq

VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval - Nasdaq

Click here to get full coverage on 41% ORR at 600 mg QD — Verastem's GFH375 shows 96.7% DCR and 92.2% 4‑month OS (ESMO 2025) - Stock Titan

41% ORR at 600 mg QD — Verastem's GFH375 shows 96.7% DCR and 92.2% 4‑month OS (ESMO 2025)  Stock Titan

41% ORR at 600 mg QD — Verastem's GFH375 shows 96.7% DCR and 92.2% 4‑month OS (ESMO 2025) - Stock Titan

Click here to get full coverage on New Analyst Forecast: $VSTM Given $13.0 Price Target - Quiver Quantitative

New Analyst Forecast: $VSTM Given $13.0 Price Target  Quiver Quantitative

New Analyst Forecast: $VSTM Given $13.0 Price Target - Quiver Quantitative

Click here to get full coverage on Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference - Business Wire

Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference  Business Wire

Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference - Business Wire

Click here to get full coverage on Verastem: The Market Is Ignoring The Progress (NASDAQ:VSTM) - Seeking Alpha

Verastem: The Market Is Ignoring The Progress (NASDAQ:VSTM)  Seeking Alpha

Verastem: The Market Is Ignoring The Progress (NASDAQ:VSTM) - Seeking Alpha

Click here to get full coverage on Verastem: Navigating Critical Steps In Commercialization And Development(Downgrade) (VSTM) - Seeking Alpha

Verastem: Navigating Critical Steps In Commercialization And Development(Downgrade) (VSTM)  Seeking Alpha

Verastem: Navigating Critical Steps In Commercialization And Development(Downgrade) (VSTM) - Seeking Alpha

Click here to get full coverage on Verastem (VSTM) Reports Q2 Loss, Misses Revenue Estimates - Nasdaq

Verastem (VSTM) Reports Q2 Loss, Misses Revenue Estimates  Nasdaq

Verastem (VSTM) Reports Q2 Loss, Misses Revenue Estimates - Nasdaq

Click here to get full coverage on Verastem Oncology Announces Proposed Public Offering of Common Stock - Business Wire

Verastem Oncology Announces Proposed Public Offering of Common Stock  Business Wire

Verastem Oncology Announces Proposed Public Offering of Common Stock - Business Wire

Click here to get full coverage on Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants - Business Wire

Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants  Business Wire

Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants - Business Wire

Click here to get full coverage on Verastem, Inc. Announces Public Offering of Common Stock and Warrants - TradingView

Verastem, Inc. Announces Public Offering of Common Stock and Warrants  TradingView

Verastem, Inc. Announces Public Offering of Common Stock and Warrants - TradingView

Click here to get full coverage on Verastem (VSTM) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance

Verastem (VSTM) Reports Q3 Loss, Tops Revenue Estimates  Yahoo Finance

Verastem (VSTM) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance

Click here to get full coverage on Verastem (VSTM) Remains Strong Despite Recent Drop in Share Pric - GuruFocus

Verastem (VSTM) Remains Strong Despite Recent Drop in Share Pric  GuruFocus

Verastem (VSTM) Remains Strong Despite Recent Drop in Share Pric - GuruFocus

Click here to get full coverage on Verastem initiated Buy at Jefferies on a potential FDA nod for ovarian cancer therapy - Seeking Alpha

Verastem initiated Buy at Jefferies on a potential FDA nod for ovarian cancer therapy  Seeking Alpha

Verastem initiated Buy at Jefferies on a potential FDA nod for ovarian cancer therapy - Seeking Alpha

Click here to get full coverage on Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors - Business Wire

Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors  Business Wire

Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors - Business Wire

Click here to get full coverage on Verastem (VSTM) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance

Verastem (VSTM) Reports Q2 Loss, Misses Revenue Estimates  Yahoo Finance

Verastem (VSTM) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance

Click here to get full coverage on Verastem (VSTM): Persistent Losses Challenge Bullish Growth Narrative Despite 55.7% Revenue Forecast - simplywall.st

Verastem (VSTM): Persistent Losses Challenge Bullish Growth Narrative Despite 55.7% Revenue Forecast  simplywall.st

Verastem (VSTM): Persistent Losses Challenge Bullish Growth Narrative Despite 55.7% Revenue Forecast - simplywall.st

Click here to get full coverage on Verastem, Inc. (NASDAQ:VSTM) Q3 2025 Earnings Call Transcript - Insider Monkey

Verastem, Inc. (NASDAQ:VSTM) Q3 2025 Earnings Call Transcript  Insider Monkey

Verastem, Inc. (NASDAQ:VSTM) Q3 2025 Earnings Call Transcript - Insider Monkey

Click here to get full coverage on Verastem stock falls after announcing public offering - Investing.com

Verastem stock falls after announcing public offering  Investing.com

Verastem stock falls after announcing public offering - Investing.com

Click here to get full coverage on VSTM - Verastem Latest Stock News & Market Updates - Stock Titan

VSTM - Verastem Latest Stock News & Market Updates  Stock Titan

VSTM - Verastem Latest Stock News & Market Updates - Stock Titan

Click here to get full coverage on Verastem (NASDAQ:VSTM) Lowered to Hold Rating by Zacks Research - MarketBeat

Verastem (NASDAQ:VSTM) Lowered to Hold Rating by Zacks Research  MarketBeat

Verastem (NASDAQ:VSTM) Lowered to Hold Rating by Zacks Research - MarketBeat

Click here to get full coverage on Verastem Inc. (VSTM) Teams Up with Leading Managers for New Offe - GuruFocus

Verastem Inc. (VSTM) Teams Up with Leading Managers for New Offe  GuruFocus

Verastem Inc. (VSTM) Teams Up with Leading Managers for New Offe - GuruFocus

Click here to get full coverage on Verastem (VSTM) Receives Positive Outlook from Mizuho Despite St - GuruFocus

Verastem (VSTM) Receives Positive Outlook from Mizuho Despite St  GuruFocus

Verastem (VSTM) Receives Positive Outlook from Mizuho Despite St - GuruFocus

Click here to get full coverage on Will Verastem’s Stock Keep Rising? - StocksToTrade

Will Verastem’s Stock Keep Rising?  StocksToTrade

Will Verastem’s Stock Keep Rising? - StocksToTrade

Click here to get full coverage on Verastem Oncology drops after $90 mln stock sale - TradingView

Verastem Oncology drops after $90 mln stock sale  TradingView

Verastem Oncology drops after $90 mln stock sale - TradingView

Click here to get full coverage on Verastem stock falls after GenFleet’s PDAC study shows lower efficacy data - Investing.com

Verastem stock falls after GenFleet’s PDAC study shows lower efficacy data  Investing.com

Verastem stock falls after GenFleet’s PDAC study shows lower efficacy data - Investing.com

Click here to get full coverage on Verastem Announces Public Offering to Raise $96.9 Million - TipRanks

Verastem Announces Public Offering to Raise $96.9 Million  TipRanks

Verastem Announces Public Offering to Raise $96.9 Million - TipRanks

Click here to get full coverage on Phase 2 Trial Shows 44% Response Rate in Ovarian Cancer Treatment | VSTM Stock News - Stock Titan

Phase 2 Trial Shows 44% Response Rate in Ovarian Cancer Treatment | VSTM Stock News  Stock Titan

Phase 2 Trial Shows 44% Response Rate in Ovarian Cancer Treatment | VSTM Stock News - Stock Titan

Click here to get full coverage on Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025 - Yahoo Finance

Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025  Yahoo Finance

Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025 - Yahoo Finance

Click here to get full coverage on Verastem (VSTM) Target Price Lowered by RBC Capital | VSTM Stock News - GuruFocus

Verastem (VSTM) Target Price Lowered by RBC Capital | VSTM Stock News  GuruFocus

Verastem (VSTM) Target Price Lowered by RBC Capital | VSTM Stock News - GuruFocus

Click here to get full coverage on Verastem stock soars after KRAS inhibitor shows strong lung cancer results - Investing.com

Verastem stock soars after KRAS inhibitor shows strong lung cancer results  Investing.com

Verastem stock soars after KRAS inhibitor shows strong lung cancer results - Investing.com

Click here to get full coverage on Verastem stock gains as Cantor Fitzgerald reiterates Overweight rating - Investing.com

Verastem stock gains as Cantor Fitzgerald reiterates Overweight rating  Investing.com

Verastem stock gains as Cantor Fitzgerald reiterates Overweight rating - Investing.com

Click here to get full coverage on Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)  Yahoo Finance

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Click here to get full coverage on Insider Sell: Dan Paterson Sells Shares of Verastem Inc (VSTM) - GuruFocus

Insider Sell: Dan Paterson Sells Shares of Verastem Inc (VSTM)  GuruFocus

Insider Sell: Dan Paterson Sells Shares of Verastem Inc (VSTM) - GuruFocus

Click here to get full coverage on Verastem Oncology to Present at Upcoming Investor Conferences - Yahoo Finance

Verastem Oncology to Present at Upcoming Investor Conferences  Yahoo Finance

Verastem Oncology to Present at Upcoming Investor Conferences - Yahoo Finance

Click here to get full coverage on Verastem: Approval Secured, Moving On To PDAC And KRAS G12D-Related Cancers - Seeking Alpha

Verastem: Approval Secured, Moving On To PDAC And KRAS G12D-Related Cancers  Seeking Alpha

Verastem: Approval Secured, Moving On To PDAC And KRAS G12D-Related Cancers - Seeking Alpha

Click here to get full coverage on Verastem Oncology Announces $75 million Private Placement - Business Wire

Verastem Oncology Announces $75 million Private Placement  Business Wire

Verastem Oncology Announces $75 million Private Placement - Business Wire

Click here to get full coverage on Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates - Yahoo Finance

Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates  Yahoo Finance

Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates - Yahoo Finance

Click here to get full coverage on Verastem Announces Promising Data from VS-7375 Study - TipRanks

Verastem Announces Promising Data from VS-7375 Study  TipRanks

Verastem Announces Promising Data from VS-7375 Study - TipRanks

Click here to get full coverage on Verastem (VSTM) Begins Clinical Trials for Potential Cancer Trea - GuruFocus

Verastem (VSTM) Begins Clinical Trials for Potential Cancer Trea  GuruFocus

Verastem (VSTM) Begins Clinical Trials for Potential Cancer Trea - GuruFocus

Click here to get full coverage on Earnings call transcript: Verastem Q3 2025 sees stock drop 7.37% premarket - Investing.com

Earnings call transcript: Verastem Q3 2025 sees stock drop 7.37% premarket  Investing.com

Earnings call transcript: Verastem Q3 2025 sees stock drop 7.37% premarket - Investing.com

Click here to get full coverage on Verastem, Inc. (NASDAQ:VSTM) Q2 2025 Earnings Call Transcript - Insider Monkey

Verastem, Inc. (NASDAQ:VSTM) Q2 2025 Earnings Call Transcript  Insider Monkey

Verastem, Inc. (NASDAQ:VSTM) Q2 2025 Earnings Call Transcript - Insider Monkey

Click here to get full coverage on What analysts say about VSTM stock - Earnings Forecast Updates & View Live Stock Forecasts Instantly - earlytimes.in

What analysts say about VSTM stock - Earnings Forecast Updates & View Live Stock Forecasts Instantly  earlytimes.in

VSTM

Price Chart

Key Statistics

Technicals

About VSTM

Latest News

Chipmakers Recap: Can VSTM stock double in next 5 years - July 2025 Short Interest & Smart Money Movement Tracker - moha.gov.vn

Insider Sell: Dan Paterson Sells 4,000 Shares of Verastem Inc (VSTM) - GuruFocus

Verastem (VSTM) Upgraded to Buy: Here's Why - Yahoo Finance

Advanced Charts

Top Gainers

Top Losers